Shots:
- The P-III (ALLEVIATE-1) study assessed analgesic efficacy of cebranopadol (400µg, QD) vs PBO for treating moderate-to-severe acute pain post abdominoplasty surgery
- Study depicted significantly reduced pain intensity as evaluated by Pain Numeric Rating Scale (NRS) AUC4-48 (1.34 mean hourly difference) and a well-tolerated safety with nausea being the common AE
- Tris will present full results of ALLEVIATE-1 at future conferences and share findings from 2 additional studies: an intranasal abuse potential study & ALLEVIATE-2 (P-III bunionectomy trial) in Q1’25, with an NDA submission planned later. Chronic pain studies for cebranopadol are set to begin in H2’25
Ref: Tris Pharma | Image: Tris Pharma
Related News:- Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
